To characterize the nature ofthyroid peroxidase (TPO) autoantibodies present in the sera of patients with autoimmune thyroid disease, we cloned three IgGl /kappa Fab fragments which bind 125I-TPO. This was accomplished by the molecular cloning and expression in bacteria of IgG gene fragments from B cells infiltrating the thyroid of a patient with Graves' disease. The three Fab fragments (SP2, SP4, and SP5) are coded for by a common heavy chain (VH1, D, JH3) and three related, but different, light chains (VK1, JK2). The SP Fab fragments bind specifically to TPO with high affinities (6 x 10-l"-2 X 10`' M) comparable to those of serum TPO autoantibodies. TPO autoantibodies represented by the SP Fab fragments are present in all 11 patients studied, constitute a high proportion (36-72%) of serum TPO autoantibodies in individual patients and interact with a conformational epitope on TPO. (J. Clin. Invest. 1992. 90:720-726.)
Introduction
Thyroid peroxidase (TPO),' the primary enzyme involved in thyroid hormone synthesis, is a large (-107 kD) membranebound glycoprotein molecule whose cDNA has been cloned (1-3). TPO is a major target of the immune system in human autoimmune thyroid disease. Until the demonstration of their identity (3) (4) (5) (6) (7) , TPO was studied as the "thyroid microsomal antigen" (8) . IgG class autoantibodies with high affinity for TPO (9) are present in the sera of patients with Hashimoto's thyroiditis or Graves' disease and may play a role in thyroid destruction (8, (10) (11) (12) .
Definition ofthe epitopes recognized by TPO autoantibodies is an important goal in understanding the pathogenesis of autoimmune thyroid disease. TPO autoantibodies appear to interact with different regions of the molecule. For example, some, but not all, TPO autoantibodies inhibit TPO enzymatic activity ( 13) and cross-react with myeloperoxidase or lactoperoxidase (14) . At the molecular level, two epitopes for serum TPO autoantibodies have been defined ( 15, 16) . Both of these epitopes are linear. However, extensive data from other antigen/antibody systems demonstrate that the majority of B cell epitopes are discontinuous and highly conformational (17, 18) . Further, decreased binding ofTPO autoantibodies to denatured TPO ( 19, 20) suggests that the majority of serum TPO autoantibodies are not directed against linear epitopes.
Human, disease-associated monoclonal TPO autoantibodies will be invaluable in defining TPO epitopes. However, such monoclonal antibodies are exceptionally difficult to generate by conventional techniques (21 ) . Recently, we obtained a human Fab fragment specific for TPO by cloning heavy and light chain immunoglobulin genes (22) from B cells infiltrating Graves' thyroid tissue (23) . In the present study, we describe the isolation of two additional TPO-specific Fab fragments from this library, as well as the expression and characterization ofall three Fab fragments. Our data indicate that TPO autoantibodies represented by these Fab fragments are present in all patients studied, constitute a high proportion of serum TPO autoantibodies in individual patients, and interact with a conformational epitope on TPO.
Methods
Molecular cloning ofTPO-binding Fabfragments. Construction of the IgGl/kappa Fab fragment combinatorial cDNA library in the vector Immunozap (Stratacyte, La Jolla, CA) has been described previously (23) . The source of the mRNA was Graves' thyroid tissue, known to contain IgG-secreting cells. The unamplified combinatorial library (3 x 10 recombinants) was screened in XLl-Blue cells by conventional techniques (24) using secreted recombinant human TPO (25), affinity purified with mouse monoclonal anti-TPO, labeled with 1251 to a specific activity of -10 ALCi/ g protein by the iodogen method (26) .
TPO-binding plaques were cloned to homogeneity and plasmids (Bluescript SK-) were excised from the Immunozap bacteriophage using the helper phage R408, according to the Stratacyte protocol. Nucleotide sequences were determined in both directions (27 (29) . Briefly, duplicate monoclonal antibody to human kappa light chains (QE 1 1; Recognition Sciences, Birmingham, UK) in a total volume of 200 gl. After 1 h at room temperature, 100 LI donkey anti-mouse Sac-cel (IDS, Boldon, Tyne and Wear, UK) was added, and the incubation continued for 30 min. After vortexing, the mixture was centrifuged for 5 min at 1,000 g to sediment the immune complexes which were then counted to determine the percent radiolabeled TPO bound. The specificity ofthis interaction was assessed by the addition of increasing amounts ( 10-12 M-10 -8 M) ofunlabeled recombinant human TPO, human myeloperoxidase (Calbiochem Corp., La Jolla, CA) or bovine lactoperoxidase (Sigma) . The affinities of the Fab fragments for TPO were determined by Scatchard analysis (30) .
Competition studies between Fabfragments and serum TPO autoantibodies. Sera from 11 patients with autoimmune thyroid disease were studied. All sera contained high levels of TPO autoantibodies (detectable by ELISA [ 31] Competition studies between Fab fragments and serum TPO antibodies ofdifferent IgG subclasses. An ELISA was used for this purpose, similar to that previously described for TPO autoantibodies measured using thyroid microsomal antigen (32) , with some modifications.
Conditioned medium (50 gl per well) from Chinese hamster ovary cells overexpressing a secreted form of TPO (25), was used to coat ELISA plates (Immulon 4; Dynatech Laboratories, Chantilly, VA) by incubation overnight at 4°C with an equal volume of bicarbonate buffer (pH 9.3). Serum TPO autoantibodies ofdifferent IgG subclasses were detected with murine monoclonal antibodies (33) to human IgG I and IgG4 (HP6012 and HP601 1, respectively; Unipath Inc., Nepean, Ontario, Canada) and IgG2 (HP6014; Sigma). Serum TPO autoantibodies with lambda light chains were detected using murine monoclonal anti-human lambda (312H; Recognition Sciences). The signal was developed with affinity-purified anti-mouse IgG conjugated to horseradish peroxidase (Sigma) and o-phenylene diamine + H202 as substrate and OD read at 492 nm. None of these murine monoclonal antibodies bound to the Fab fragments. Competition studies were performed by incubating sera (appropriately diluted) with or without increasing concentrations of SP2 Fab fragment.
Screening of TPO cDNA fragment library. Construction of the library and the method used for screening has been described previously (34) . Reactivity of Fab fragment SP2 was assessed using the murine anti-kappa antibody (QE1 1; Recognition Sciences) followed by affinity-purified anti-mouse IgG horseradish peroxidase conjugate (Cappel Laboratories, West Chester, PA). As a positive control, we used a murine monoclonal antibody (#40.28), generated against denatured TPO (35) , which recognizes a linear epitope expressed in this library.
Interaction between Fab fragments and denatured TPO. TPO in conditioned culture medium (described above) was reduced and alkylated using dithiothreitol and iodoacetamide ( 19). ELISA plates were coated with native or denatured TPO, as described above. Binding of SP2, SP4, and SP5 (10-' M) was detected, as described above for serum TPO lambda autoantibodies, using monoclonal anti-kappa (QEl 1). Mouse monoclonal antibody (#40.28, diluted 1:100) and control ascites (NS-1, diluted 1:50; Cappel) were included as positive and negative controls respectively.
Results
Nucleotide and derived amino-acid sequences of TPO-binding Fabfragments. Further screening of the Fab fragment combinatorial cDNA library for radiolabeled TPO binding yielded two additional Fab fragments (SP4 and SP5). The heavy chains of SP4 and SP5 were identical to that of previously isolated SP2 (23) . The light chains of SP4 and SP5, although closely related to that of SP2, differed in their nucleotide (Figs. 1 and 3 ) and derived amino acid (Figs. 2 and 3) sequences. All three light chains are coded for by VKI and JK2, the closest germ-line genes being HUMIGKLVJ (GenBank accession number D90158) and KV312 (36), respectively.
Regarding the VK region, the SP4 and SP5 amino acid sequences are more homologous (90%) to HUMIGKLVJ than SP2 (83%). Only the kappa chain of SP2 has a potential glycosylation site, N-X-S, in the CDR1 (Fig. 2 ). Unlike SP2, in which the J segment is identical to the germline gene KV3 12, SP4 and SP5 (which are identical to each other) have four nucleotide substitutions, one of which results in an L to V change (Fig. 3 ).
Specificity and affinity of TPO-binding Fab fragments.
Binding of the SP2 Fab fragment to 1251-TPO was readily displaced by unlabeled TPO but not by myeloperoxidase or lactoperoxidase (Fig. 4 A) . SP4 and SP5 displayed the same specificity for TPO (data not shown). As determined by Scatchard analysis, the affinities for TPO of all three Fab fragments were remarkably high (Fig. 4 B) . SP2 and SP5 displayed similar affinities (Kd 6-8 x 10"1 M). The affinity of SP4 was slightly lower( 2 x 10-10 M).
Competition studies between Fab fragments and serum TPO autoantibodies. We determined the abilities of SP2, SP4, or SP5 to compete with TPO autoantibodies in patients' sera for binding to 1251I-TPO. Increasing amounts of SP2 (l10-1o-10 -7 M) progressively inhibited the binding to TPO by all of 11 sera from patients with autoimmune thyroid disease that were tested (Fig. 5 ). In the individual 11 sera, maximum inhibition ranged from 36 to 72%. The results obtained for five of these sera were similar with all three Fab fragments: 55±2% (mean % inhibition±SEM) for SP2, 49+8% for SP5, and 43±6% for SP4.
Competition studies attempting to determine whether or not the inhibitory effects of SP2, SP4, and SP5 were additive were inconclusive because ofthe inability to attain high enough Fab fragment concentrations. Because SP2, SP4, and SP5 have identical heavy chains and similar light chains belonging to the same VK gene family, it is reasonable to assume that they bind to the same, or closely related, epitope. This assumption is supported by studies in mice demonstrating that high affinity binding to a specific epitope is usually achieved by recombination of the same heavy chain with light chains of the same family (37).
Competition studies between Fab fragments and serum TPO autoantibodies of different subclasses and lambda light chain. Sera from individual patients contain different proportions of TPO antibodies of subclasses IgG1 and IgG4 and, in some patients, IgG2 (32, 38 9 sera analyzed are shown (Fig. 6 ). In one patient (Fig. 6 A) Confirmation that the epitope recognised by SP2 (and also by SP4 and SP5) is conformational was obtained in ELISA studies using native recombinant TPO and TPO denatured by reduction and alkylation. The three Fab fragments bound less well to denatured than to native TPO (Fig. 7) . In contrast, binding of mouse monoclonal #40.28 was higher to denatured than to intact TPO.
Discussion
The TPO-specific Fab fragments SP2, SP4 and SP5 all have the heavy chain variable region sequence previously reported for SP2 (23) . The VH region is a member of the VHI family The present data indicate that the SP epitope is recognized by 36-72% of the TPO autoantibodies present in the sera of individual patients. As yet, there is no information of the proportion of TPO autoantibodies within an individual patient which recognize one or both of the linear epitopes mentioned above. The present data also indicate that patients' autoantibodies against the SP epitope are not restricted to a single IgG subclass. Thus, in some patients the SP epitope is predominantly IgGl, in others IgG4, and in a few IgG2. IgG3 TPO autoantibodies are only rarely present (32, 38) . There is no information on the IgG subclass distribution or light chain type of autoantibodies against the linear epitopes described above. In terms oflight chain type, the SP epitope is recognized poorly by TPO autoantibodies with lambda light chains. The SP epitope-recognizing antibodies in the patient population are, therefore, likely to contain kappa light chains, like the SP Fab fragments themselves.
Techniques previously available to study TPO 
